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ENCEPHALITIS WITH CLINICAL FEATURES OF
RASMUSSEN ENCEPHALITIS
Anti-Hu antibodies (anti-neuronal nuclear antibod-
ies, type 1) are associated with paraneoplastic enceph-
alomyelitis in adults, especially those with small cell
lung cancer. Anti-Hu antibodies are extremely rare
in children, but they have been observed in neuro-
blastoma with or without opsoclonus-myoclonus syn-
drome or in limbic encephalitis without associated
malignancy.1 However, anti-Hu antibodies are not
typically associated with clinical features of Rasmussen
encephalitis (RE).
Case history. We present a 5-year-old right-handed
girl meeting clinical, EEG, and MRI diagnostic
criteria for RE2 but with elevated serum and CSF
anti-Hu antibodies. She was asymptomatic until age
4, when she developed simple partial seizures with
right face and arm clonic movements without
epilepsia partialis continua (EPC). She then
developed right lower facial weakness, dysarthria,
and stagnation in cognition and learning. EEG
showed left hemispheric slowing and left
frontotemporal focal seizures. Serial MRIs showed
progressive left-greater-than-right hemispheric
atrophy and left frontal, temporal, insular and
caudate greater than right frontal and temporal
T2 signal hyperintensity (figure). She had no
personality changes, ataxia, opsoclonus, movement
disorders, dysautonomia, neuropathy, or myopathy.
Diagnostic evaluation 1 year after symptom
onset included serum and CSF inflammatory
markers and antibodies (including anti-glutamic
acid decarboxylase, anti-NMDA receptor, anti-
contactin-associated protein 2, and anti-leucine-
rich glioma-inactivated 1 protein). Results were
notable for elevated anti-Hu antibody titers (Mayo
Clinic Paraneoplastic Antibody Panel immunofluo-
rescence assay3) in serum (1:960, normal ,1:240)
and CSF (1:16, normal ,1:2), 13 CSF oligoclonal
bands, and CSF neopterin of 67 nmol/L (normal 7–
40 nmol/L) without significant pleocytosis (2 white
and 0 red blood cells per mm3) or high titers of
other anti-neuronal antibodies. Serum striational
antibody titer was 1:3,840 (normal ,1:120) with
normal anti-acetylcholine receptor (AChR) anti-
body and normal collapsin response-mediator
protein 5 immunoglobulin (CRMP-5-IgG). Serum
thyroperoxidase (TPO) antibody was 15.6 IU/mL
(normal ,15 IU/mL) with normal thyroid func-
tion. Head magnetic resonance angiogram and
malignancy workup including whole-body MRI,
urine homovanillic acid, and urine vanillylmandelic
acid were unremarkable.
Treatment has included 3 courses of methylprednis-
olone 30 mg/kg/mo, 7 courses of cyclophosphamide
750 mg/m2/mo, and maintenance immunotherapy
with mycophenolate mofetil 600 mg/m2/d. Eleven
months after her diagnosis, her seizure frequency has
improved from once daily to once weekly on levetira-
cetam and lacosamide, her right facial weakness has
resolved, and her mother notes improvement in school
performance.
Discussion. We describe a novel presentation of
anti-Hu–associated encephalitis with features of
RE.2 Cases of anti-Hu–associated EPC have been
reported with focal cortical lesions but without
hemispheric atrophy or other RE features.4–6 Nota-
bly, our patient has no malignancy, opsoclonus-
myoclonus, or limbic encephalitis, which are
typically seen in pediatric anti-Hu–associated
encephalitis.1
Anti-Hu antibodies are not thought to be
directly toxic but have been associated with the
presence of Hu-specific T cells.1 This could direct
T cell–mediated cytotoxicity considered to be a
pathophysiologic mechanism of RE.2 Anti-Hu–
associated encephalitis, as in our patient, is most
commonly treated with IV immunoglobulins,
cyclophosphamide, and/or methylprednisolone.
Since both anti-Hu–associated encephalitis and
RE involve T cell–mediated cytotoxicity, T cell–
directed treatments may be particularly useful. Fur-
thermore, as anti-Hu–associated cytotoxicity could
further affect her contralateral hemisphere, hemi-
spherectomy alone may not be sufficient to control
her seizures and may not be curative.
Our patient has predominantly unilateral hemi-
spheric atrophy, but she also has mild contralateral
atrophy and T2 hyperintensity. Diffuse cerebral
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damage may be due to the fact that Hu antigens are
expressed by all neurons.1 The pathophysiology
underlying unilaterally predominant atrophy is
unclear given that Hu antigens are ubiquitously ex-
pressed. In a previous case of anti-Hu encephalitis,
Hu antigen neuronal expression variability was
hypothesized to underlie focal pathologic features.4
In addition to high anti-Hu titers, our patient also
had mild elevation of 2 other autoantibodies, as has
been noted previously.3 Anti-TPO levels in Hashimoto
thyroiditis and encephalopathy are .100–1,000
IU/mL. An anti-TPO level of 15.6 is likely not
pathogenic. Anti-striated muscle antibodies are clas-
sically elevated in thymoma-associated myasthenia,
although they are nonspecific and may be a generic
marker of autoimmunity. Absence of myasthenic
features and normal anti-AChR antibody and
CRMP-5-IgG make thymoma-associated myasthenia
unlikely.7 Anti-Hu antibodies may also be a nonspe-
cific inflammatory marker. Noting the difficulty of
comparing titers across labs, our patient’s serum
anti-Hu titer is lower than in previous pediatric cases
(.1:10,000), but it is still 4 times the upper normal
limit.1
This case provides insights into the anti-Hu–
associated neurologic disorder spectrum. New-onset
refractory focal seizures or focal cerebral atrophy,
including RE, could be a presentation of anti-Hu–
associated encephalitis. Thorough evaluations for
autoimmune etiologies should be strongly consid-
ered, especially because this could potentially guide
treatment.
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